Amgen Inc logo

AMGN - Amgen Inc Share Price

$227.73 5.8  2.6%

Last Trade - 05/03/21

Large Cap
Market Cap £95.03bn
Enterprise Value £111.17bn
Revenue £18.37bn
Position in Universe 90th / 6651
Unlock AMGN Revenue
Relative Strength (%)
1m -1.31%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -17.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
21,662 22,991 22,849 23,747 23,362 25,424 26,458 27,419 +3.3%
+27.7 +12.1 +11.5 +14.0 -0.5 -4.9 +37.1 +9.06
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, Amgen,Inc. revenues increased 9% to $25.42B. Net income decreased7% to $7.26B. Revenues reflect Otezla segment increase from$178M to $2.2B, Other products segment increase of 19% to$6.57B, US segment increase of 9% to $17.99B, ROW segmentincrease of 10% to $6.26B. Net income was offset by Selling, general and administrative - Ba increase of 9% to $4.77B(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for AMGN
Graphical History


AMGN Revenue Unlock AMGN Revenue

Net Income

AMGN Net Income Unlock AMGN Revenue

Normalised EPS

AMGN Normalised EPS Unlock AMGN Revenue

PE Ratio Range

AMGN PE Ratio Range Unlock AMGN Revenue

Dividend Yield Range

AMGN Dividend Yield Range Unlock AMGN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AMGN EPS Forecasts Unlock AMGN Revenue
Profile Summary

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated October 31, 1986
Public Since May 1, 1987
No. of Shareholders: 5,336
No. of Employees: 24,300
Sector Healthcare
Industry Pharmaceuticals
Index Dow Jones Composite , Dow Jones Industrial Average , Nasdaq Composite , Nasdaq 100 , S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange NASDAQ Global Select Market
Shares in Issue 577,566,383
Free Float (0.0%)
Eligible for
AMGN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for AMGN
Upcoming Events for AMGN
Wednesday 28th April, 2021 Estimate
Q1 2021 Amgen Inc Earnings Release
Frequently Asked Questions for Amgen Inc
What is the Amgen Inc share price?

As of 05/03/21, shares in Amgen Inc are trading at $227.73, giving the company a market capitalisation of £95.03bn. This share price information is delayed by 15 minutes.

How has the Amgen Inc share price performed this year?

Shares in Amgen Inc are currently trading at $227.73 and the price has moved by 7.36% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Amgen Inc price has moved by -15.32% over the past year.

What are the analyst and broker recommendations for Amgen Inc?

Of the analysts with advisory recommendations for Amgen Inc, there are there are currently 7 "buy" , 14 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Amgen Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Amgen Inc next release its financial results?

Amgen Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Amgen Inc dividend yield?

The Amgen Inc dividend yield is 2.81% based on the trailing twelve month period.

Does Amgen Inc pay a dividend?

Last year, Amgen Inc paid a total dividend of 6.4, and it currently has a trailing dividend yield of 2.81%. Looking ahead, shares in Amgen Inc are due to go ex-dividend on 2021-05-14 and the next dividend pay date is 2021-03-08.

When does Amgen Inc next pay dividends?

Amgen Inc are due to go ex-dividend on 2021-05-14 and the next dividend pay date is 2021-03-08. The historic dividend yield on Amgen Inc shares is currently 2.81%.

How do I buy Amgen Inc shares?

To buy shares in Amgen Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Amgen Inc?

Shares in Amgen Inc are currently trading at $227.73, giving the company a market capitalisation of £95.03bn.

Where are Amgen Inc shares listed? Where are Amgen Inc shares listed?

Here are the trading details for Amgen Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: AMGN
What kind of share is Amgen Inc?

Based on an overall assessment of its quality, value and momentum, Amgen Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Amgen Inc share price forecast 2021?

Shares in Amgen Inc are currently priced at $227.73. At that level they are trading at 11.62% discount to the analyst consensus target price of 0.00.

Analysts covering Amgen Inc currently have a consensus Earnings Per Share (EPS) forecast of 16.881 for the next financial year.

How can I tell whether the Amgen Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Amgen Inc. Over the past six months, the relative strength of its shares against the market has been -18.94%. At the current price of $227.73, shares in Amgen Inc are trading at -3.92% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Amgen Inc PE Ratio?

The Amgen Inc PE ratio based on its reported earnings over the past 12 months is 18.5. The shares are currently trading at $227.73.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Amgen Inc?

Amgen Inc's management team is headed by:

Robert Bradway - CHM
Cynthia Patton - SVP
Robert Eckert - LED
Gregory Garland - IND
David Piacquad - SVP
Fred Hassan - IND
Jonathan Graham - SVP
Lori Johnston - SVP
Esteban Santos - EVP
Wanda Austin - IND
Brian Druker - IND
David Reese - EVP
Murdo Gordon - EVP
Peter Griffith - CFO
Linda Louie - CAO
Who are the major shareholders of Amgen Inc?

Here are the top five shareholders of Amgen Inc based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.18% (47.2m shares)
Capital Research Global Investors Investment Advisor
Percentage owned: 5.5% (31.8m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.5% (31.8m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 5.21% (30.1m shares)
PRIMECAP Management Company Investment Advisor
Percentage owned: 2.94% (17.0m shares)
Similar to AMGN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.